Table 1.
Baseline characteristics (total) and by change in estimated glomerular filtration rate (eGFR).
| Overall N=435 | In-Hospital eGFR Decline N=232 | In-Hospital eGFR Increase N=203 | |
|---|---|---|---|
| Age, years | 67.0 ± 13.2 | 66.6 ± 12.7 | 67.4 ± 13.9 |
| Female | 108 (24.8) | 66 (28.4) | 42 (20.7) |
| Black | 104 (23.9) | 53 (22.8) | 51 (25.1) |
| BMI, kg/m2 | 33.9 ± 9.5 | 35.2 ± 10.2 | 32.4 ± 8.4 |
| Ejection Fraction, % | 35.2 ± 17.6 | 38.0 ± 17.7 | 34.2 ± 17.4 |
| Ischemic etiology | 259 (59.5) | 138 (59.5) | 121 (59.6) |
| NYHA Functional Class | |||
| 2 | 10 ( 2.5) | 6 ( 2.8) | 4 ( 2.2) |
| 3 | 248 (61.8) | 131 (60.9) | 117 (62.9) |
| 4 | 143 (35.7) | 78 (36.3) | 65 (34.9) |
| Hypertension | 354 (81.4) | 193 (83.2) | 161 (79.3) |
| Diabetes | 253 (58.2) | 149 (64.2) | 104 (51.2) |
| Baseline Laboratory Results | |||
| NT-proBNP, pg/ml | 4509 [2323, 9985] | 4080 [2125, 7885] | 5178 [2511, 12905] |
| Creatinine, mg/dl | 1.67 [1.21, 2.11] | 1.52 [1.14, 2.04] | 1.75 [1.37, 2.22] |
| eGFR, ml/min/1.73 m2 | 40.0 [29.4, 59.2] | 41.7 [31.4, 65.1] | 37.3 [28.4, 53.9] |
| Hemoglobin, g/dl | 11.4 ± 1.9 | 11.4 ± 1.9 | 11.5 ± 2.0 |
| Medications | |||
| ACEI or ARB | 251 (57.7) | 131 (56.5) | 120 (59.1) |
| Aldosterone antagonist | 108 (24.8) | 66 (28.4) | 42 (20.7) |
| Loop diuretic | 423 (97.2) | 226 (97.4) | 197 (97.0) |
| CARRESS Trial | |||
| Ultrafiltration Arm | 83 (19.1) | 42 (18.5) | 41 (20.2) |
| Medical Therapy Arm | 86 (19.8) | 43 (18.5) | 43 (21.2) |
| DOSE Trial | |||
| Bolus, low dose | 67 (15.4) | 42 (18.1) | 41 (20.2) |
| Bolus, high dose | 69 (15.9) | 42 (18.1) | 27 (13.3) |
| Continuous, low dose | 64 (14.7) | 28 (12.1) | 36 (17.7) |
| Continuous, high dose | 66 (15.2) | 35 (15.1) | 31 (15.3) |
Values are represented by mean ± standard deviation, or median [25th and 75th interquartile range], or n (%).
Abbreviations: BMI, body mass index; NYHA, New York Heart Association; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; eGFR, estimated glomerular filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker